In silico assessment of the binding of reported bioactive compounds from Phaseolus vulgaris L. (Fabaceae) towards the wild-type and mutant estrogen receptor-alpha

Robertson G. Rivera, Joanna V. Toralba, Junie B. Billones


Background:  Breast cancer is one of the leading causes of deaths in women worldwide, affecting nearly 7.8 million people. In 2020 in the Philippines, there were around 150,000 Filipinos who were newly diagnosed with the disease. The complex pathogenesis of breast cancer in addition to the emergence of resistance to therapy makes the treatment very challenging. Compounds that can antagonize the effects of estradiol towards ER-α, especially the mutant Y537S type are sought for.

Objectives: The focus of this study was the in-silico assessment of the reported secondary metabolites from Phaseolus vulgaris L. (fam. Fabaceae) towards the wild-type and mutant ER-α. Bioisosteric replacement was conducted to generate analogs that can possibly have a comparable binding affinity as estradiol towards estrogen receptors alpha.

Results: Majority of the secondary metabolites present in Phaseolus vulgaris L. belong to the group of
phytoestrogens, phytosterols, and plant hormones. These groups of compounds exhibited favorable binding energies toward the wild-type and mutant (Y537S) estrogen receptors alpha. Moreover, they bind to the same ligand binding pocket as estradiol, involving similar interactions and amino acid residues.

Conclusion:  Compounds from Phaseolus vulgaris L. can potentially target ER-α. Four gibberellin A19 analogs were generated that exhibited favorable binding towards the wild- and mutant- ER-α and may be further optimized to obtain a promisin gcompound against breast cancer.


breast cancer; ER-α; Phaseolus vulgaris L.; in silico screening; molecular docking; Baguio beans

Full Text:



  • There are currently no refbacks.

Print ISSN: 2704-3517; Online ISSN: 2738-042X